Mayo Clinic has set a new milestone in organ transplantation, completing a record total of 2,065 solid organ transplants across its facilities in Minnesota, Arizona, and Florida in 2025. This achievement marks the highest number of transplants performed by the institution in its history and positions it as the leading hospital system for such procedures in the United States.
Record-Breaking Year for Transplants
“2025 was a record year,” stated Julie Heimbach, a Mayo transplant surgeon and director of the hospital’s Rochester transplant center. She noted that the total surpassed the previous year’s figures, which were already part of a trend of record-setting volumes over the last three years. “We have consistently been among the nation’s highest volume transplant centers,” Heimbach added, highlighting the ongoing commitment to advancing transplant capabilities.
The surge in transplant numbers is attributed to a combination of factors, including the generous contributions from donors and their families as well as innovative advancements within the field. Heimbach emphasized that the hospital’s surgical teams are increasingly equipped to handle more complex cases with positive outcomes.
Innovative techniques, such as a method where Mayo Clinic employs a machine to continuously pump oxygenated blood through donor organs, have significantly enhanced the viability of transplants. This process not only preserves the organ longer but also allows for functional assessments and even repairs before the transplant occurs. “This method helps ensure that more donated organs can travel farther distances and work better for the recipient,” Heimbach explained.
Focus on Rejection Prevention
Research at Mayo Clinic is also directed towards minimizing the risk of organ rejection, a common concern for transplant recipients. When an organ is transplanted, the recipient’s immune system may begin to reject it. While some rejection types can be reversed, chronic rejection presents more complex challenges. Heimbach described it as “a more insidious process where there’s scar tissue that just keeps building up,” which complicates treatment.
To combat this issue, Mayo Clinic is conducting a clinical trial to evaluate the effectiveness of a specialized type of stem cell aimed at promoting healing and reducing inflammation and scar tissue development in kidney transplant recipients. Heimbach stated that if this trial proves successful, it could have extensive implications for transplant medicine and patient outcomes.
Currently, over 100,000 people are awaiting life-saving organ transplants in the United States, underscoring the critical importance of ongoing advancements in transplant technology and donor engagement initiatives. The success of Mayo Clinic’s programs not only offers hope to those in need but also sets a benchmark for organ transplantation practices globally.
